Alternative CAR T cell constructs are currently being investigated that can enhance the CAR T cells efficacy in the tumor microenvironment by increasing the ability of CAR-T cells to infiltrate tumors, bind BCMA, and proliferate in response to antigen recognition. Here, TNFRSF17 is linked to neoplasm.